The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb
This article was originally published in The Pink Sheet Daily
Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.
You may also be interested in...
Sepsis trials designed with narrower enrollment criteria could allow treatment effects to emerge, countering the “signal to noise” problem that has plagued late-stage trials in sepsis, researchers suggest.
With current technology and resources, a well-funded in vitro diagnostics company can create and pursue a strategy of information gathering and informatics application to create medical knowledge, enabling it to assume the risk and manage certain segments of patients. But few if any pharma or diagnostics firms appear poised to take advantage.
Japan's Asahi Kasei Pharma announced Nov. 22 that its acquisition of Massachusetts-based Artisan Pharma, a company it spun out in 2006.